These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2017-002698-20 A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD) 2019-05-14 due-trials
Ongoing 2018-003298-90 Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema not-yet-due